Belvedere Trading’s ImmunityBio IBRX Stock Holding History

Belvedere Trading’s Portfolio IBRX Stock Details IBRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-3,400	Closed	-$9.45K	–	782
2023 Q2	$9.45K	Buy	3,400 +1,400	+70%	+$3.96K	﹤0.01%	724
2023 Q1	$3.64K	Sell	2,000 -24,400	-92%	-$75.9K	﹤0.01%	801
2022 Q4	$134K	Buy	+26,400	New	+$145K	﹤0.01%	416

Other funds holding IBRX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Belvedere Trading's IBRX Position: Q2 2023 in Review

Belvedere Trading sold out of ImmunityBio (IBRX) in Q2 2023, closing a stake of 11,846 shares — an estimated $33.5K sold.

Belvedere Trading first reported a position in IBRX in Q2 2022 and held it in 4 quarters. The position peaked at $101K in Q4 2022. 117 funds tracked by Wall St. Rank hold IBRX as of Q2 2023.

Belvedere Trading reported no remaining ImmunityBio position as of Q2 2023 after selling out during the quarter.
Belvedere Trading sold 11,846 ImmunityBio shares in Q2 2023, an estimated $33.5K.
Belvedere Trading first reported a position in ImmunityBio in Q2 2022 and held it in 4 quarters.
Belvedere Trading's ImmunityBio position peaked at $101K in Q4 2022.
117 funds tracked by Wall St. Rank held ImmunityBio as of Q2 2023.

Based on Belvedere Trading's 13F filing for Q2 2023, filed 8 Aug 2023.